

*Entered w/ RCE  
JEP  
3/4/08*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: MOZES2A

In re Application of:	)	Conf. No.: 9655
	)	
Edna MOZES et al.	)	Art Unit: 1644
	)	
Appln. No.: 10/620,621	)	Examiner: G. R. Ewoldt
	)	
Filed: July 17, 2003	)	Washington, D.C.
	)	
For: SYNTHETIC PEPTIDES AND	)	January 3, 2008
PHARMACEUTICAL	)	
COMPOSITIONS COMPRISING ...	)	

RESPONSE

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Randolph Building, Mail Stop Amendments  
401 Dulany Street  
Alexandria, VA 22314

Sir:

*DD  
not  
enter  
1842  
2/1/08*

The present communication is responsive to the official action of July 10, 2007. Claims 1-15 presently appear in this case. No claims have been allowed. The official action of July 10, 2007, has now been carefully studied. Reconsideration and allowance are hereby respectfully urged.

Briefly, the present invention relates to the use of certain synthetic peptides for the treatment of systemic lupus erythematosus (SLE). The synthetic peptides are based on a complementarity-determining region (CDR) of the heavy or light chain of a pathogenic anti-DNA monoclonal antibody that induces an SLE-like disease in mice, or a salt or derivative